CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial
The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine, dimming hopes that it could help fill the world’s great need. The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest…
Details